Technical Analysis for PRLD - Prelude Therapeutics Incorporated
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Very Strong | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Lower Bollinger Band Walk | Weakness | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Gapped Up | Strength | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| New 52 Week Closing Low | Bearish | 3.33% | |
| Expansion Breakdown | Bearish Swing Setup | 3.33% | |
| Volume Surge | Other | 3.33% | |
| Lower Bollinger Band Walk | Weakness | 3.33% | |
| New 52 Week Low | Weakness | 3.33% | |
| Earnings Movers | Other | 3.33% |
| Alert | Time |
|---|---|
| 60 Minute Opening Range Breakdown | about 20 hours ago |
| Rose Above Previous Day's High | about 23 hours ago |
| Up 5% | about 23 hours ago |
| Up 10% | about 23 hours ago |
| Gap Up Partially Closed | about 24 hours ago |
Get a Trading Assistant
- Earnings date: 10/30/2024
Prelude Therapeutics Incorporated Description
Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule therapies optimized to target the key driver mechanisms in cancers. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies in patients who are refractory to or intolerant of established therapies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme and primary central nervous system lymphomas. The company is also developing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a potent inhibitor of CDK9 that exhibits high kinome selectivity; PRT-SCA2 for multiple genomically selected cancers; and PRT-K4 for solid tumors. Prelude Therapeutics Incorporated was founded in 2016 and is based in Wilmington, Delaware.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Solid Tumors Lymphoma Blastoma Glioblastoma Protein Kinase Inhibitor Tyrosine Kinase Receptors Small Molecule Therapies Glioblastoma Multiforme Phosphoinositide 3 Kinase Inhibitor
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 6.8 |
| 52 Week Low | 1.1 |
| Average Volume | 372,398 |
| 200-Day Moving Average | 3.93 |
| 50-Day Moving Average | 2.85 |
| 20-Day Moving Average | 1.72 |
| 10-Day Moving Average | 1.49 |
| Average True Range | 0.18 |
| RSI (14) | 21.26 |
| ADX | 51.33 |
| +DI | 7.44 |
| -DI | 39.82 |
| Chandelier Exit (Long, 3 ATRs) | 1.55 |
| Chandelier Exit (Short, 3 ATRs) | 1.63 |
| Upper Bollinger Bands | 2.24 |
| Lower Bollinger Band | 1.19 |
| Percent B (%b) | 0.05 |
| BandWidth | 61.26 |
| MACD Line | -0.40 |
| MACD Signal Line | -0.42 |
| MACD Histogram | 0.0206 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.39 | ||||
| Resistance 3 (R3) | 1.40 | 1.37 | 1.36 | ||
| Resistance 2 (R2) | 1.37 | 1.33 | 1.36 | 1.35 | |
| Resistance 1 (R1) | 1.31 | 1.31 | 1.29 | 1.29 | 1.35 |
| Pivot Point | 1.27 | 1.27 | 1.26 | 1.26 | 1.27 |
| Support 1 (S1) | 1.21 | 1.24 | 1.19 | 1.19 | 1.13 |
| Support 2 (S2) | 1.17 | 1.21 | 1.17 | 1.13 | |
| Support 3 (S3) | 1.11 | 1.17 | 1.12 | ||
| Support 4 (S4) | 1.09 |
